Publications

Back to Publications

Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

N Engl J Med 2020:211–20

Morand et al demonstrate a greater BICLA response at Week 52 for patients treated with anifrolumab versus those treated with placebo.

Significant benefits of anifrolumab versus placebo were also seen in glucocorticoid dose and severity of skin disease. A greater frequency of HZ was seen in patients treated with anifrolumab versus placebo.

Keywords:


LinkedIn